GlassScriptPhysician profile
Meredith O Morse
NPI 1790148518
$9,138.17
in general payments reported to CMS, 2019-2025
29 companies · $1,738 in 2025
The $1,738 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $704 · 2020: $16.46 · 2021: $1,054 · 2022: $2,116 · 2023: $1,881 · 2024: $1,629 · 2025: $1,738.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,045 · Education: $203.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,045.00 |
| Education | $203.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,118.41 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $999.74 | 2022-2025 | Sotyktu |
| Genzyme Corporation | $798.99 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $591.37 | 2021-2025 | Dupixent, Libtayo |
| Pfizer INC. | $578.37 | 2021-2025 | |
| Janssen Biotech, INC. | $517.81 | 2021-2025 | Tremfya, Simponi Aria, Simponi |
| Novartis Pharmaceuticals Corporation | $428.60 | 2021-2025 | |
| Galderma Laboratories, L.P. | $416.33 | 2021-2025 | Nemluvio, Aklief, Epsolay |
| Celgene Corporation | $387.14 | 2019 | |
| Lilly USA, LLC | $356.39 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Leo Pharma INC. | $342.83 | 2021-2025 | Adbry, Anzupgo |
| Arcutis Biotherapeutics, INC. | $234.24 | 2023-2025 | Zoryve |
| Ucb, INC. | $207.60 | 2022-2025 | Bimzelx |
| Incyte Corporation | $191.10 | 2021-2025 | Opzelura |
| Sun Pharmaceutical Industries INC. | $184.57 | 2024-2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $149.99 | 2022 | |
| Vyne Pharmaceuticals INC. | $131.26 | 2021 | |
| Allergan, INC. | $96.00 | 2020-2022 | |
| Dermavant Sciences, INC. | $82.34 | 2023-2024 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $75.56 | 2021-2025 | Siliq |
| Amgen INC. | $58.13 | 2021-2024 | Otezla |
| Almirall LLC | $35.06 | 2025 | Seysara, Klisyri |
| Verrica Pharmaceuticals INC. | $33.85 | 2024 | Ycanth |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.40 | 2024 | Cyltezo |
| Journey Medical Corporation | $27.48 | 2023 | |
| Genentech USA, INC. | $24.74 | 2025 | Xolair |
| Biofrontera INC. | $20.09 | 2025 | |
| Sandoz INC. | $14.52 | 2021 | |
| Organon LLC | $3.26 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meredith Morse listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.